Percutaneous treatment of renal cysts with OK-432 sclerosis.
OBJECTIVE
The aim of this study was to demonstrate OK- 432 sclerotherapy efficacy for treatment of simple renal cysts.


METHODS
Twenty patients with 25 symptomatic or large simple cysts were treated by ultrasonography (US)-guided percutaneous aspiration and injection of OK-432 (8 men and 12 women, mean age 63.6 years, SD 9.5). Six patients presented with flank pain, 14 presented with renal mass; renal cyst location was right, left, or bilateral sided in 9, 8, and 8 kidneys, respectively. Patients were evaluated by clinical assessment, US, or CT scan 3 months following the procedure. Complete and partial success was defined as symptom resolution with either total cyst ablation or greater than 70% reduction, respectively. Failure was defined as 30% of cyst size recurrence and/or persistent symptoms.


RESULTS
Average reduction was 93.0%. Complete and partial resolution occurred in 11 (44.0%) and 13 (52.0%) cysts, respectively. One case was defined as failure, with a 64.2% size reduction from 10.9cm to 3.9cm (volume reduction rate 95.4%). Renal pain improved in all patients, regardless of complete or partial resolution. Minor complications occurred in 3 patients, 2 developed leukocytosis and 1 had mild fever (< 38.5 degrees C) following aspiration and sclerotherapy. Successful treatment was achieved with conservative measures and NSAID therapy.


CONCLUSIONS
Percutaneous treatment of simple renal cysts with OK-432 sclerotherapy was found to be a safe, effective and minimally invasive procedure.
Choi
Young Deuk
YD
Department of Urology, Yonsei University College of Medicine, 134 Sinchon-Dong, Seodaemun-Gu, Seoul, Korea. youngd74@yumc.yonsei.ac.kr
Cho
Soung Yong
SY
Cho
Kang Su
KS
Lee
Dong Hoon
DH
Lee
Seung Hwan
SH
D000328:Adult; D000368:Aged; D005260:Female; D007839:Functional Laterality; D006801:Humans; D052177:Kidney Diseases, Cystic / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects; D016896:Treatment Outcome
D010844:Picibanil